Patients who receive an autologous hematopoietic (stem) cell transplant (AHCT) have a 10 to 30 percent chance of getting shingles. Shingles can cause a rash that may be followed by nerve pain in the area where the rash healed, called postherpetic neuralgia, which can last for months or years.
The purpose of this study is to evaluate the effectiveness of an investigational vaccine, called V212, for protecting recipients of AHCT against shingles. This vaccine is similar to a marketed shingles and chicken pox vaccine, except that it has been modified to make it safe for people with weakened immune systems. Patients in this study will be randomly assigned to receive V212 or a placebo.